Navigation Links
Arete Therapeutics Bolsters Management Team
Date:10/29/2008

Appoints Euan MacIntyre, Ph.D. as Senior Vice President of Drug Discovery

HAYWARD, Calif., Oct. 29 /PRNewswire/ -- Arete Therapeutics Inc., a privately-held biopharmaceutical company developing first-in-class soluble epoxide hydrolase (s-EH) inhibitors, today named D. Euan MacIntyre, Ph.D., to the newly-created position of Senior Vice President, Drug Discovery. Dr. MacIntyre brings over 20 years of pharmaceutical drug discovery and development leadership to Arete Therapeutics.

"We are extremely pleased to welcome Euan as a member of our executive management team, as his broad drug discovery expertise and disease-specific knowledge will bolster our ability to develop effective s-EH inhibitors," said James H. Sabry, M.D., Ph.D., President and Chief Executive Officer of Arete Therapeutics. "Given his scientific accomplishments and exceptional track record in advancing discovery programs through clinical development, I am confident Euan will provide invaluable insights and leadership as we finalize our plans to initiate a phase II study of AR9281 to treat metabolic syndrome and build out our expertise in this unique area of biology."

Dr. MacIntyre comes to Arete after more than 22 years with Merck Research Laboratories, where he held positions of escalating importance, most recently as Vice President of Pharmacology. Under his leadership, Dr. MacIntyre's team identified and validated several compounds now commercially available or in clinical trials for a variety of diseases and conditions including emesis, diabetes, obesity, hypertension, hyperlipidemia, pain, urinary incontinence and immuno-inflammatory disorders. In addition to his experience in discovery and development, Dr. MacIntyre evaluated numerous in-licensing candidates and served as a member of several joint research committees for Merck's joint ventures and collaborations. Dr. MacIntyre received his Ph.D. in pharmacology and experimental pathology from the University of Cambridge. H
'/>"/>

SOURCE Arete Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
2. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
3. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
4. Nile Therapeutics to Present at the 7th Annual BIO Investor Forum
5. Nektar Therapeutics to Webcast R&D Day on November 12th
6. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
7. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
8. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
9. CV Therapeutics to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008
10. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
11. United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... 34-year veteran of the high-technology industry, ...s development and intellectual property management...ace. The company also plans to invest in promisin...or. , Monterey, CA (PRWEB...r veteran of the high-technology industry, has for...
(Date:11/30/2009)...ternational team of applied scientists from Harvar...rated compact, multibeam, and multi-wavelength las...ectrum (infrared). By contrast, typical lasers emi.... The innovative multibeam lasers have potential u...ing pollution monitoring, optical wireless, and in...
(Date:11/30/2009)...wswire/ -- Acuo Technologies, developers of high-p... migration tools and services, today announced con...ew Vendor Neutral Archive (VNA), providing the fou... of hospitals, clinics and affiliates. ,, The a...s DICOM Services Grid(TM) Software. The Acuo VNA ...
(Date:11/30/2009)...ire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) a...hat the company will be presenting at the 21st Ann...9 at 12:30 pm local time at The New York Palace, N...company,s business strategy, research and developm...he live audio only presentation can be accessed vi...
Breaking Biology Technology:Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 2Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 3Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 4Scientists demonstrate multibeam, multi-functional lasers 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 3NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference 2
... resonance image of a hand. Source: Kemie Guaida. ...ralian-based Intelligent Image Management will lic...re imaging systems. , ,TeraMedica,s Intelligent Im...lian company based its name, is TeraMedica,s archi...tly from imaging devices or to work with picture a...
...w there are at least five different types of paten...include: (1) a search for competitors patents, (2)...4) a right-to-use search and (5) a patent validity...egy and a different goal. , 1. A search for compet...s typically performed on a periodic basis and look...
...omething new is happening in American business. , ...of things are still wretchedly out of whack about ...it, but in little ways, people are starting to act...mes when you least expect it). , ,Right here in th...examples of the HF in action. , ,A friend goes on ...
Other Biology Technology:Australian company will sell TeraMedica's medical imaging software 2Five ways your company can benefit from patent searches 2Five ways your company can benefit from patent searches 3'Don't work here' job interviews set new Midwest technology trend 2'Don't work here' job interviews set new Midwest technology trend 3'Don't work here' job interviews set new Midwest technology trend 4'Don't work here' job interviews set new Midwest technology trend 5
(Date:11/30/2009)...irst comprehensive review of the state of Antarcti...imate system is published this week (Tuesday 1 Dec...search (SCAR). The review - Antarctic Climate Cha...rch from the icy continent, identifies areas for f...t questions that policy makers have about Antarcti...
(Date:11/30/2009)...BURGHA University of Pittsburgh team overcame a ma...ls such as those that could lead to more efficient... exhaust less toxic. The researchers reported Nov....of high-temperature stability in metallic nanopart...red by a vulnerability to extreme heat. , Gtz Ve...
(Date:11/30/2009)...ditors of The Journal of Experimental Biology ar...entre National de la Recherche Scientifique (CNRS)...winner of this year,s JEB Outstanding Paper Priz...tanding achievement and is intended to encourage y...ditor-in-Chief, and adds that ,we truly appreciate...
Breaking Biology News(10 mins):First comprehensive review of the state of Antarctica's climate 2First metallic nanoparticles resistant to extreme heat 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4FoodBizDaily com Announces New Free Report International Trade Opportunity 3A The Brazilian Acai Berry 54107 1FoodBizDaily com Announces New Free Report International Trade Opportunity 3A The Brazilian Acai Berry 54107 2Bionovo Announces Second Quarter 2009 Highlights and Financial Results 4842 1Bionovo Announces Second Quarter 2009 Highlights and Financial Results 4842 2Bionovo Announces Second Quarter 2009 Highlights and Financial Results 4842 3Bionovo Announces Second Quarter 2009 Highlights and Financial Results 4842 4Bionovo Announces Second Quarter 2009 Highlights and Financial Results 4842 5Bionovo Announces Second Quarter 2009 Highlights and Financial Results 4842 6Bionovo Announces Second Quarter 2009 Highlights and Financial Results 4842 7Bionovo Announces Second Quarter 2009 Highlights and Financial Results 4842 8More Evidence Healthy Living Brings Long Life 54102 1More Evidence Healthy Living Brings Long Life 54102 2More Evidence Healthy Living Brings Long Life 54102 3
...issions from using coal are set to double by 2030,...of mitigating global climate change. In view of t... it is vital to minimise emissions where coal is u...nded the launch of the Near Zero Emissions Coal (N...m of this study is to look at the feasibility of b...
... amounts of lead in children,s blood -- amounts we...iated with reduced IQ scores, finds a new six-year...lead exposure on cognitive function in children wh...s for Disease Control and Prevention (CDC) standar... 100 parts per billion. The researchers compared c...
...diseases such as malaria and dengue cause sufferin...s at least one million deaths annually, and is par... five. In addition to the human toll, these disea...mmunities that can least afford it. Various appro...icides, vaccine development, and preventive medici...
Other Biology News:UK scientists lead China closer to carbon capture and storage 2Even minute levels of lead cause brain damage in children 2Selfish DNA and the Genetic Control of Vector-Borne Diseases 2Selfish DNA and the Genetic Control of Vector-Borne Diseases 3
...'s family of light scattering instruments. The HTm...ph and enables you to get multi-angle light scatte... easily installed in the oven of any Waters 150C, ...get three angles of light scattering data taken si...
CD25 MicroBeads, non-human primate from Miltenyi Biotec
...es, for 10 chips, provides the reagents and suppli...ysis (picogram levels) with 10 chips on the Experi...1,250 microliters RNA gel, 20 microliters RNA High...ters RNA HighSens loading buffer, 100 microliters ...
Mouse Anti-Verotoxin II (Shiga-like) A subunit (SLT-2a) Monoclonal Antibody, Unconjugated, Clone 557 from Meridian Life Science, Inc.
Biology Products: